nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—RET—autonomic nervous system—attention deficit hyperactivity disorder	0.0158	0.0259	CbGeAlD
Ruxolitinib—GRK1—forebrain—attention deficit hyperactivity disorder	0.00963	0.0158	CbGeAlD
Ruxolitinib—PRKCE—forebrain—attention deficit hyperactivity disorder	0.00942	0.0154	CbGeAlD
Ruxolitinib—PRKG2—cardiovascular system—attention deficit hyperactivity disorder	0.00854	0.014	CbGeAlD
Ruxolitinib—RPS6KA6—cardiovascular system—attention deficit hyperactivity disorder	0.00766	0.0125	CbGeAlD
Ruxolitinib—CAMK1—forebrain—attention deficit hyperactivity disorder	0.00707	0.0116	CbGeAlD
Ruxolitinib—MARK2—forebrain—attention deficit hyperactivity disorder	0.00686	0.0112	CbGeAlD
Ruxolitinib—ANKK1—nervous system—attention deficit hyperactivity disorder	0.00661	0.0108	CbGeAlD
Ruxolitinib—PLK3—cardiovascular system—attention deficit hyperactivity disorder	0.00639	0.0105	CbGeAlD
Ruxolitinib—JAK1—forebrain—attention deficit hyperactivity disorder	0.0058	0.00949	CbGeAlD
Ruxolitinib—DCLK1—forebrain—attention deficit hyperactivity disorder	0.0058	0.00949	CbGeAlD
Ruxolitinib—CAMK1D—forebrain—attention deficit hyperactivity disorder	0.00566	0.00926	CbGeAlD
Ruxolitinib—PRKG2—nervous system—attention deficit hyperactivity disorder	0.00548	0.00897	CbGeAlD
Ruxolitinib—HIPK2—forebrain—attention deficit hyperactivity disorder	0.00541	0.00886	CbGeAlD
Ruxolitinib—PRKG2—central nervous system—attention deficit hyperactivity disorder	0.00528	0.00864	CbGeAlD
Ruxolitinib—GRK1—nervous system—attention deficit hyperactivity disorder	0.00523	0.00856	CbGeAlD
Ruxolitinib—PRKCE—nervous system—attention deficit hyperactivity disorder	0.00512	0.00837	CbGeAlD
Ruxolitinib—GRK1—central nervous system—attention deficit hyperactivity disorder	0.00503	0.00824	CbGeAlD
Ruxolitinib—ROCK1—forebrain—attention deficit hyperactivity disorder	0.00499	0.00817	CbGeAlD
Ruxolitinib—PRKCE—central nervous system—attention deficit hyperactivity disorder	0.00493	0.00806	CbGeAlD
Ruxolitinib—PLK1—nervous system—attention deficit hyperactivity disorder	0.00492	0.00804	CbGeAlD
Ruxolitinib—RPS6KA6—nervous system—attention deficit hyperactivity disorder	0.00492	0.00804	CbGeAlD
Ruxolitinib—MAST1—nervous system—attention deficit hyperactivity disorder	0.00492	0.00804	CbGeAlD
Ruxolitinib—JAK1—cardiovascular system—attention deficit hyperactivity disorder	0.0049	0.00802	CbGeAlD
Ruxolitinib—DYRK1A—forebrain—attention deficit hyperactivity disorder	0.00487	0.00797	CbGeAlD
Ruxolitinib—BMPR2—forebrain—attention deficit hyperactivity disorder	0.00485	0.00794	CbGeAlD
Ruxolitinib—PRKCE—cerebellum—attention deficit hyperactivity disorder	0.00481	0.00788	CbGeAlD
Ruxolitinib—PLK1—central nervous system—attention deficit hyperactivity disorder	0.00473	0.00775	CbGeAlD
Ruxolitinib—RPS6KA6—central nervous system—attention deficit hyperactivity disorder	0.00473	0.00775	CbGeAlD
Ruxolitinib—MAST1—central nervous system—attention deficit hyperactivity disorder	0.00473	0.00775	CbGeAlD
Ruxolitinib—DCLK3—nervous system—attention deficit hyperactivity disorder	0.00466	0.00763	CbGeAlD
Ruxolitinib—RPS6KA6—cerebellum—attention deficit hyperactivity disorder	0.00463	0.00757	CbGeAlD
Ruxolitinib—MAST1—cerebellum—attention deficit hyperactivity disorder	0.00463	0.00757	CbGeAlD
Ruxolitinib—HIPK2—cardiovascular system—attention deficit hyperactivity disorder	0.00458	0.00749	CbGeAlD
Ruxolitinib—DCLK3—central nervous system—attention deficit hyperactivity disorder	0.00449	0.00734	CbGeAlD
Ruxolitinib—DAPK3—cardiovascular system—attention deficit hyperactivity disorder	0.0044	0.0072	CbGeAlD
Ruxolitinib—CAMK2G—forebrain—attention deficit hyperactivity disorder	0.00434	0.0071	CbGeAlD
Ruxolitinib—BMP2K—forebrain—attention deficit hyperactivity disorder	0.00434	0.0071	CbGeAlD
Ruxolitinib—LRRK2—forebrain—attention deficit hyperactivity disorder	0.0043	0.00704	CbGeAlD
Ruxolitinib—ROCK1—cardiovascular system—attention deficit hyperactivity disorder	0.00422	0.00691	CbGeAlD
Ruxolitinib—PRKG2—brain—attention deficit hyperactivity disorder	0.00419	0.00686	CbGeAlD
Ruxolitinib—DYRK1A—cardiovascular system—attention deficit hyperactivity disorder	0.00412	0.00674	CbGeAlD
Ruxolitinib—PLK3—nervous system—attention deficit hyperactivity disorder	0.0041	0.00671	CbGeAlD
Ruxolitinib—BMPR2—cardiovascular system—attention deficit hyperactivity disorder	0.0041	0.00671	CbGeAlD
Ruxolitinib—GRK1—brain—attention deficit hyperactivity disorder	0.004	0.00654	CbGeAlD
Ruxolitinib—PLK3—central nervous system—attention deficit hyperactivity disorder	0.00395	0.00646	CbGeAlD
Ruxolitinib—PRKCE—brain—attention deficit hyperactivity disorder	0.00391	0.0064	CbGeAlD
Ruxolitinib—CAMK1—nervous system—attention deficit hyperactivity disorder	0.00384	0.00628	CbGeAlD
Ruxolitinib—JAK1—midbrain—attention deficit hyperactivity disorder	0.00383	0.00627	CbGeAlD
Ruxolitinib—DCLK1—midbrain—attention deficit hyperactivity disorder	0.00383	0.00627	CbGeAlD
Ruxolitinib—PLK1—brain—attention deficit hyperactivity disorder	0.00376	0.00615	CbGeAlD
Ruxolitinib—RPS6KA6—brain—attention deficit hyperactivity disorder	0.00376	0.00615	CbGeAlD
Ruxolitinib—MAST1—brain—attention deficit hyperactivity disorder	0.00376	0.00615	CbGeAlD
Ruxolitinib—MARK2—nervous system—attention deficit hyperactivity disorder	0.00372	0.0061	CbGeAlD
Ruxolitinib—CAMK1—central nervous system—attention deficit hyperactivity disorder	0.00369	0.00605	CbGeAlD
Ruxolitinib—CAMK2G—cardiovascular system—attention deficit hyperactivity disorder	0.00367	0.00601	CbGeAlD
Ruxolitinib—DAPK2—midbrain—attention deficit hyperactivity disorder	0.00365	0.00598	CbGeAlD
Ruxolitinib—CAMK1—cerebellum—attention deficit hyperactivity disorder	0.00361	0.00591	CbGeAlD
Ruxolitinib—MARK2—central nervous system—attention deficit hyperactivity disorder	0.00359	0.00587	CbGeAlD
Ruxolitinib—DCLK3—brain—attention deficit hyperactivity disorder	0.00356	0.00583	CbGeAlD
Ruxolitinib—MARK2—cerebellum—attention deficit hyperactivity disorder	0.00351	0.00574	CbGeAlD
Ruxolitinib—JAK2—forebrain—attention deficit hyperactivity disorder	0.00349	0.00571	CbGeAlD
Ruxolitinib—DAPK3—midbrain—attention deficit hyperactivity disorder	0.00343	0.00562	CbGeAlD
Ruxolitinib—TAOK2—cerebellum—attention deficit hyperactivity disorder	0.00324	0.00531	CbGeAlD
Ruxolitinib—TYK2—cardiovascular system—attention deficit hyperactivity disorder	0.00324	0.00531	CbGeAlD
Ruxolitinib—BMPR2—midbrain—attention deficit hyperactivity disorder	0.0032	0.00524	CbGeAlD
Ruxolitinib—MKNK2—cardiovascular system—attention deficit hyperactivity disorder	0.0032	0.00524	CbGeAlD
Ruxolitinib—JAK3—nervous system—attention deficit hyperactivity disorder	0.00317	0.00518	CbGeAlD
Ruxolitinib—DCLK1—nervous system—attention deficit hyperactivity disorder	0.00315	0.00515	CbGeAlD
Ruxolitinib—JAK1—nervous system—attention deficit hyperactivity disorder	0.00315	0.00515	CbGeAlD
Ruxolitinib—PLK3—brain—attention deficit hyperactivity disorder	0.00314	0.00513	CbGeAlD
Ruxolitinib—CAMK1D—nervous system—attention deficit hyperactivity disorder	0.00307	0.00503	CbGeAlD
Ruxolitinib—TAOK3—forebrain—attention deficit hyperactivity disorder	0.00306	0.00502	CbGeAlD
Ruxolitinib—PHKG2—nervous system—attention deficit hyperactivity disorder	0.00305	0.005	CbGeAlD
Ruxolitinib—JAK3—central nervous system—attention deficit hyperactivity disorder	0.00305	0.00499	CbGeAlD
Ruxolitinib—JAK1—central nervous system—attention deficit hyperactivity disorder	0.00303	0.00496	CbGeAlD
Ruxolitinib—DCLK1—central nervous system—attention deficit hyperactivity disorder	0.00303	0.00496	CbGeAlD
Ruxolitinib—LTK—brain—attention deficit hyperactivity disorder	0.00303	0.00496	CbGeAlD
Ruxolitinib—JAK3—cerebellum—attention deficit hyperactivity disorder	0.00298	0.00488	CbGeAlD
Ruxolitinib—DCLK1—cerebellum—attention deficit hyperactivity disorder	0.00296	0.00485	CbGeAlD
Ruxolitinib—JAK1—cerebellum—attention deficit hyperactivity disorder	0.00296	0.00485	CbGeAlD
Ruxolitinib—CAMK1D—central nervous system—attention deficit hyperactivity disorder	0.00296	0.00484	CbGeAlD
Ruxolitinib—STK16—nervous system—attention deficit hyperactivity disorder	0.00295	0.00483	CbGeAlD
Ruxolitinib—JAK2—cardiovascular system—attention deficit hyperactivity disorder	0.00295	0.00483	CbGeAlD
Ruxolitinib—PHKG2—central nervous system—attention deficit hyperactivity disorder	0.00294	0.00481	CbGeAlD
Ruxolitinib—HIPK2—nervous system—attention deficit hyperactivity disorder	0.00294	0.00481	CbGeAlD
Ruxolitinib—CAMK1—brain—attention deficit hyperactivity disorder	0.00293	0.0048	CbGeAlD
Ruxolitinib—CAMK1D—cerebellum—attention deficit hyperactivity disorder	0.00289	0.00473	CbGeAlD
Ruxolitinib—MAP3K19—nervous system—attention deficit hyperactivity disorder	0.00288	0.00471	CbGeAlD
Ruxolitinib—PHKG2—cerebellum—attention deficit hyperactivity disorder	0.00287	0.0047	CbGeAlD
Ruxolitinib—CAMK2G—midbrain—attention deficit hyperactivity disorder	0.00287	0.00469	CbGeAlD
Ruxolitinib—BMP2K—midbrain—attention deficit hyperactivity disorder	0.00287	0.00469	CbGeAlD
Ruxolitinib—MARK2—brain—attention deficit hyperactivity disorder	0.00285	0.00466	CbGeAlD
Ruxolitinib—STK16—central nervous system—attention deficit hyperactivity disorder	0.00284	0.00465	CbGeAlD
Ruxolitinib—MAP3K3—cardiovascular system—attention deficit hyperactivity disorder	0.00284	0.00465	CbGeAlD
Ruxolitinib—LRRK2—midbrain—attention deficit hyperactivity disorder	0.00284	0.00465	CbGeAlD
Ruxolitinib—HIPK2—central nervous system—attention deficit hyperactivity disorder	0.00283	0.00463	CbGeAlD
Ruxolitinib—DAPK2—cerebellum—attention deficit hyperactivity disorder	0.00283	0.00462	CbGeAlD
Ruxolitinib—DAPK3—nervous system—attention deficit hyperactivity disorder	0.00282	0.00462	CbGeAlD
Ruxolitinib—CLK2—nervous system—attention deficit hyperactivity disorder	0.0028	0.00458	CbGeAlD
Ruxolitinib—STK16—cerebellum—attention deficit hyperactivity disorder	0.00278	0.00455	CbGeAlD
Ruxolitinib—MAP3K19—central nervous system—attention deficit hyperactivity disorder	0.00277	0.00454	CbGeAlD
Ruxolitinib—HIPK2—cerebellum—attention deficit hyperactivity disorder	0.00277	0.00453	CbGeAlD
Ruxolitinib—DAPK3—central nervous system—attention deficit hyperactivity disorder	0.00272	0.00445	CbGeAlD
Ruxolitinib—ROCK1—nervous system—attention deficit hyperactivity disorder	0.00271	0.00444	CbGeAlD
Ruxolitinib—CLK2—central nervous system—attention deficit hyperactivity disorder	0.00269	0.00441	CbGeAlD
Ruxolitinib—DAPK3—cerebellum—attention deficit hyperactivity disorder	0.00266	0.00435	CbGeAlD
Ruxolitinib—DYRK1A—nervous system—attention deficit hyperactivity disorder	0.00264	0.00433	CbGeAlD
Ruxolitinib—TAOK2—brain—attention deficit hyperactivity disorder	0.00263	0.00431	CbGeAlD
Ruxolitinib—BMPR2—nervous system—attention deficit hyperactivity disorder	0.00263	0.00431	CbGeAlD
Ruxolitinib—CLK2—cerebellum—attention deficit hyperactivity disorder	0.00263	0.00431	CbGeAlD
Ruxolitinib—ROCK1—central nervous system—attention deficit hyperactivity disorder	0.00261	0.00427	CbGeAlD
Ruxolitinib—TAOK3—cardiovascular system—attention deficit hyperactivity disorder	0.00259	0.00424	CbGeAlD
Ruxolitinib—MAP3K7—midbrain—attention deficit hyperactivity disorder	0.00258	0.00422	CbGeAlD
Ruxolitinib—DYRK1A—central nervous system—attention deficit hyperactivity disorder	0.00255	0.00417	CbGeAlD
Ruxolitinib—BMPR2—central nervous system—attention deficit hyperactivity disorder	0.00253	0.00415	CbGeAlD
Ruxolitinib—TYK2—midbrain—attention deficit hyperactivity disorder	0.00253	0.00414	CbGeAlD
Ruxolitinib—IRAK1—midbrain—attention deficit hyperactivity disorder	0.0025	0.00409	CbGeAlD
Ruxolitinib—MKNK2—midbrain—attention deficit hyperactivity disorder	0.0025	0.00409	CbGeAlD
Ruxolitinib—DYRK1A—cerebellum—attention deficit hyperactivity disorder	0.00249	0.00407	CbGeAlD
Ruxolitinib—BMPR2—cerebellum—attention deficit hyperactivity disorder	0.00248	0.00406	CbGeAlD
Ruxolitinib—RET—midbrain—attention deficit hyperactivity disorder	0.00244	0.00399	CbGeAlD
Ruxolitinib—JAK3—brain—attention deficit hyperactivity disorder	0.00242	0.00396	CbGeAlD
Ruxolitinib—JAK1—brain—attention deficit hyperactivity disorder	0.00241	0.00394	CbGeAlD
Ruxolitinib—DCLK1—brain—attention deficit hyperactivity disorder	0.00241	0.00394	CbGeAlD
Ruxolitinib—PLK4—brain—attention deficit hyperactivity disorder	0.00239	0.00391	CbGeAlD
Ruxolitinib—NUAK2—cerebellum—attention deficit hyperactivity disorder	0.00237	0.00388	CbGeAlD
Ruxolitinib—CAMK2G—nervous system—attention deficit hyperactivity disorder	0.00236	0.00386	CbGeAlD
Ruxolitinib—BMP2K—nervous system—attention deficit hyperactivity disorder	0.00236	0.00386	CbGeAlD
Ruxolitinib—CAMK1D—brain—attention deficit hyperactivity disorder	0.00235	0.00384	CbGeAlD
Ruxolitinib—LRRK2—nervous system—attention deficit hyperactivity disorder	0.00234	0.00382	CbGeAlD
Ruxolitinib—PHKG2—brain—attention deficit hyperactivity disorder	0.00233	0.00382	CbGeAlD
Ruxolitinib—DAPK2—brain—attention deficit hyperactivity disorder	0.0023	0.00376	CbGeAlD
Ruxolitinib—CAMK2G—central nervous system—attention deficit hyperactivity disorder	0.00227	0.00371	CbGeAlD
Ruxolitinib—BMP2K—central nervous system—attention deficit hyperactivity disorder	0.00227	0.00371	CbGeAlD
Ruxolitinib—STK16—brain—attention deficit hyperactivity disorder	0.00226	0.0037	CbGeAlD
Ruxolitinib—LRRK2—central nervous system—attention deficit hyperactivity disorder	0.00225	0.00368	CbGeAlD
Ruxolitinib—HIPK2—brain—attention deficit hyperactivity disorder	0.00225	0.00368	CbGeAlD
Ruxolitinib—MAP3K3—midbrain—attention deficit hyperactivity disorder	0.00222	0.00363	CbGeAlD
Ruxolitinib—BMP2K—cerebellum—attention deficit hyperactivity disorder	0.00222	0.00363	CbGeAlD
Ruxolitinib—CAMK2G—cerebellum—attention deficit hyperactivity disorder	0.00222	0.00363	CbGeAlD
Ruxolitinib—MAP3K19—brain—attention deficit hyperactivity disorder	0.0022	0.0036	CbGeAlD
Ruxolitinib—LRRK2—cerebellum—attention deficit hyperactivity disorder	0.0022	0.0036	CbGeAlD
Ruxolitinib—DAPK3—brain—attention deficit hyperactivity disorder	0.00216	0.00353	CbGeAlD
Ruxolitinib—MAP3K2—nervous system—attention deficit hyperactivity disorder	0.00214	0.0035	CbGeAlD
Ruxolitinib—CLK2—brain—attention deficit hyperactivity disorder	0.00214	0.0035	CbGeAlD
Ruxolitinib—TYK2—nervous system—attention deficit hyperactivity disorder	0.00208	0.00341	CbGeAlD
Ruxolitinib—ROCK1—brain—attention deficit hyperactivity disorder	0.00207	0.00339	CbGeAlD
Ruxolitinib—MAP3K2—central nervous system—attention deficit hyperactivity disorder	0.00206	0.00337	CbGeAlD
Ruxolitinib—MKNK2—nervous system—attention deficit hyperactivity disorder	0.00205	0.00336	CbGeAlD
Ruxolitinib—TAOK3—midbrain—attention deficit hyperactivity disorder	0.00202	0.00331	CbGeAlD
Ruxolitinib—DYRK1A—brain—attention deficit hyperactivity disorder	0.00202	0.00331	CbGeAlD
Ruxolitinib—MAP3K2—cerebellum—attention deficit hyperactivity disorder	0.00201	0.0033	CbGeAlD
Ruxolitinib—BMPR2—brain—attention deficit hyperactivity disorder	0.00201	0.00329	CbGeAlD
Ruxolitinib—TYK2—central nervous system—attention deficit hyperactivity disorder	0.002	0.00328	CbGeAlD
Ruxolitinib—RET—nervous system—attention deficit hyperactivity disorder	0.002	0.00328	CbGeAlD
Ruxolitinib—MAP3K7—cerebellum—attention deficit hyperactivity disorder	0.00199	0.00326	CbGeAlD
Ruxolitinib—MKNK2—central nervous system—attention deficit hyperactivity disorder	0.00198	0.00324	CbGeAlD
Ruxolitinib—TYK2—cerebellum—attention deficit hyperactivity disorder	0.00196	0.00321	CbGeAlD
Ruxolitinib—MKNK2—cerebellum—attention deficit hyperactivity disorder	0.00193	0.00316	CbGeAlD
Ruxolitinib—IRAK1—cerebellum—attention deficit hyperactivity disorder	0.00193	0.00316	CbGeAlD
Ruxolitinib—RET—central nervous system—attention deficit hyperactivity disorder	0.00193	0.00316	CbGeAlD
Ruxolitinib—NUAK2—brain—attention deficit hyperactivity disorder	0.00192	0.00315	CbGeAlD
Ruxolitinib—JAK2—nervous system—attention deficit hyperactivity disorder	0.00189	0.0031	CbGeAlD
Ruxolitinib—RET—cerebellum—attention deficit hyperactivity disorder	0.00189	0.00309	CbGeAlD
Ruxolitinib—MAP3K3—nervous system—attention deficit hyperactivity disorder	0.00182	0.00299	CbGeAlD
Ruxolitinib—JAK2—central nervous system—attention deficit hyperactivity disorder	0.00182	0.00298	CbGeAlD
Ruxolitinib—CAMK2G—brain—attention deficit hyperactivity disorder	0.0018	0.00295	CbGeAlD
Ruxolitinib—BMP2K—brain—attention deficit hyperactivity disorder	0.0018	0.00295	CbGeAlD
Ruxolitinib—LRRK2—brain—attention deficit hyperactivity disorder	0.00178	0.00292	CbGeAlD
Ruxolitinib—JAK2—cerebellum—attention deficit hyperactivity disorder	0.00178	0.00292	CbGeAlD
Ruxolitinib—MAP3K3—central nervous system—attention deficit hyperactivity disorder	0.00176	0.00288	CbGeAlD
Ruxolitinib—MAP3K3—cerebellum—attention deficit hyperactivity disorder	0.00172	0.00281	CbGeAlD
Ruxolitinib—TAOK3—nervous system—attention deficit hyperactivity disorder	0.00166	0.00272	CbGeAlD
Ruxolitinib—MAP3K2—brain—attention deficit hyperactivity disorder	0.00164	0.00268	CbGeAlD
Ruxolitinib—MAP3K7—brain—attention deficit hyperactivity disorder	0.00162	0.00265	CbGeAlD
Ruxolitinib—TAOK3—central nervous system—attention deficit hyperactivity disorder	0.0016	0.00262	CbGeAlD
Ruxolitinib—TYK2—brain—attention deficit hyperactivity disorder	0.00159	0.0026	CbGeAlD
Ruxolitinib—IRAK1—brain—attention deficit hyperactivity disorder	0.00157	0.00257	CbGeAlD
Ruxolitinib—MKNK2—brain—attention deficit hyperactivity disorder	0.00157	0.00257	CbGeAlD
Ruxolitinib—TAOK3—cerebellum—attention deficit hyperactivity disorder	0.00157	0.00256	CbGeAlD
Ruxolitinib—RET—brain—attention deficit hyperactivity disorder	0.00153	0.00251	CbGeAlD
Ruxolitinib—JAK2—brain—attention deficit hyperactivity disorder	0.00145	0.00237	CbGeAlD
Ruxolitinib—MAP3K3—brain—attention deficit hyperactivity disorder	0.00139	0.00228	CbGeAlD
Ruxolitinib—TAOK3—brain—attention deficit hyperactivity disorder	0.00127	0.00208	CbGeAlD
Ruxolitinib—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000505	0.000827	CbGeAlD
Ruxolitinib—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000487	0.000797	CbGeAlD
Ruxolitinib—BMPR2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000253	0.000651	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000253	0.000651	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000253	0.000651	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000253	0.000649	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000252	0.000647	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000251	0.000645	CbGpPWpGaD
Ruxolitinib—CAMK2G—Cellular responses to stress—EP300—attention deficit hyperactivity disorder	0.000251	0.000645	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000249	0.000641	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000249	0.00064	CbGpPWpGaD
Ruxolitinib—MAP3K7—TGF-beta Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.000248	0.000637	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000247	0.000636	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000247	0.000635	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000246	0.000632	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000246	0.000632	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000243	0.000625	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000243	0.000623	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—SNAP25—attention deficit hyperactivity disorder	0.000242	0.000623	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000238	0.000613	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.000237	0.00061	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—COMT—attention deficit hyperactivity disorder	0.000237	0.000609	CbGpPWpGaD
Ruxolitinib—DYRK1A—Cell Cycle—EP300—attention deficit hyperactivity disorder	0.000237	0.000608	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000235	0.000605	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000235	0.000604	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000234	0.000601	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000233	0.000599	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MB21D1—attention deficit hyperactivity disorder	0.000232	0.000597	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—POLR3A—attention deficit hyperactivity disorder	0.000232	0.000596	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000231	0.000593	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00023	0.000591	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000229	0.000589	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000228	0.000587	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000228	0.000586	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000226	0.000581	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STUB1—attention deficit hyperactivity disorder	0.000225	0.000578	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—POLR3A—attention deficit hyperactivity disorder	0.000225	0.000578	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000224	0.000577	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000223	0.000574	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000223	0.000572	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000221	0.000567	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00022	0.000565	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000219	0.000563	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000219	0.000562	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000219	0.000562	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—POLR3A—attention deficit hyperactivity disorder	0.000218	0.000561	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000216	0.000555	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000215	0.000553	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000215	0.000553	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000215	0.000552	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000212	0.000546	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000212	0.000546	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000212	0.000544	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000211	0.000543	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000209	0.000537	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000209	0.000536	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STUB1—attention deficit hyperactivity disorder	0.000208	0.000534	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000207	0.000533	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000205	0.000527	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000202	0.000519	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000201	0.000517	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000199	0.000511	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000199	0.000511	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000198	0.000509	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000198	0.000508	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000196	0.000504	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000195	0.000502	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000194	0.000499	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.000194	0.000498	CbGpPWpGaD
Ruxolitinib—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000193	0.000496	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000193	0.000496	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000192	0.000493	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00019	0.000487	CbGpPWpGaD
Ruxolitinib—JAK2—Factors involved in megakaryocyte development and platelet production—EP300—attention deficit hyperactivity disorder	0.000189	0.000486	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000189	0.000485	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle, Mitotic—EP300—attention deficit hyperactivity disorder	0.000189	0.000485	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000186	0.000479	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000186	0.000478	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000183	0.00047	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000183	0.000469	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00018	0.000462	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000177	0.000456	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000176	0.000453	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000176	0.000453	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—SNAP25—attention deficit hyperactivity disorder	0.000176	0.000452	CbGpPWpGaD
Ruxolitinib—PLK4—Cell Cycle, Mitotic—EP300—attention deficit hyperactivity disorder	0.000176	0.000452	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—POLR3A—attention deficit hyperactivity disorder	0.00017	0.000438	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00017	0.000437	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00017	0.000436	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle—EP300—attention deficit hyperactivity disorder	0.000169	0.000433	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000166	0.000428	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000166	0.000426	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000165	0.000424	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000164	0.000423	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000164	0.000421	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000163	0.000419	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000163	0.000418	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000162	0.000415	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000162	0.000415	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00016	0.000412	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00016	0.000411	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.00016	0.00041	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000158	0.000407	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000158	0.000407	CbGpPWpGaD
Ruxolitinib—PLK4—Cell Cycle—EP300—attention deficit hyperactivity disorder	0.000157	0.000404	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000157	0.000403	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000154	0.000396	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000154	0.000396	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000154	0.000395	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000152	0.00039	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000149	0.000383	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000149	0.000383	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000149	0.000382	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000149	0.000382	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000147	0.000377	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000147	0.000377	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000145	0.000374	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000145	0.000372	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000144	0.000369	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000143	0.000368	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000141	0.000362	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000139	0.000357	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000139	0.000356	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000138	0.000355	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000137	0.000353	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000136	0.000351	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000135	0.000347	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000135	0.000346	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—EP300—attention deficit hyperactivity disorder	0.000134	0.000345	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000133	0.000341	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00013	0.000335	CbGpPWpGaD
Ruxolitinib—JAK2—Chromatin modifying enzymes—EP300—attention deficit hyperactivity disorder	0.00013	0.000334	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—SNAP25—attention deficit hyperactivity disorder	0.00013	0.000334	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000129	0.00033	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000128	0.000329	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000126	0.000324	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000126	0.000323	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000125	0.000323	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000125	0.000321	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000124	0.00032	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000123	0.000317	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling by Wnt—EP300—attention deficit hyperactivity disorder	0.000123	0.000316	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000122	0.000315	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000122	0.000315	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—EP300—attention deficit hyperactivity disorder	0.000121	0.000312	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000121	0.000312	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000121	0.000311	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.00012	0.00031	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00012	0.000309	CbGpPWpGaD
Ruxolitinib—PRKG2—Metabolism—EP300—attention deficit hyperactivity disorder	0.00012	0.000307	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000119	0.000307	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000118	0.000305	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000118	0.000304	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000117	0.000302	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000117	0.000302	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000117	0.0003	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000116	0.000298	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000115	0.000297	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000115	0.000296	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000114	0.000293	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000113	0.000291	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000113	0.000289	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000112	0.000288	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000111	0.000286	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00011	0.000282	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000109	0.000279	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000108	0.000277	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000106	0.000273	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000106	0.000273	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000104	0.000268	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000103	0.000266	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000103	0.000264	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000102	0.000263	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000102	0.000262	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—EP300—attention deficit hyperactivity disorder	0.000102	0.000261	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000101	0.000259	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.99e-05	0.000257	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SNAP25—attention deficit hyperactivity disorder	9.85e-05	0.000253	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.79e-05	0.000252	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.49e-05	0.000244	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	9.45e-05	0.000243	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.4e-05	0.000242	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.37e-05	0.000241	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.1e-05	0.000234	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.08e-05	0.000233	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.92e-05	0.000229	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—EP300—attention deficit hyperactivity disorder	8.89e-05	0.000229	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.82e-05	0.000227	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.81e-05	0.000227	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.81e-05	0.000227	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.79e-05	0.000226	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.66e-05	0.000223	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.55e-05	0.00022	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.55e-05	0.00022	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—EP300—attention deficit hyperactivity disorder	8.53e-05	0.000219	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.5e-05	0.000218	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	8.49e-05	0.000218	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.4e-05	0.000216	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.3e-05	0.000213	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.21e-05	0.000211	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—EP300—attention deficit hyperactivity disorder	8.09e-05	0.000208	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.97e-05	0.000205	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	7.89e-05	0.000203	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—EP300—attention deficit hyperactivity disorder	7.88e-05	0.000203	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—EP300—attention deficit hyperactivity disorder	7.85e-05	0.000202	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—EP300—attention deficit hyperactivity disorder	7.82e-05	0.000201	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.73e-05	0.000199	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—EP300—attention deficit hyperactivity disorder	7.63e-05	0.000196	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—EP300—attention deficit hyperactivity disorder	7.62e-05	0.000196	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.56e-05	0.000194	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.44e-05	0.000191	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.42e-05	0.000191	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—EP300—attention deficit hyperactivity disorder	7.2e-05	0.000185	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	7.16e-05	0.000184	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.9e-05	0.000177	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—EP300—attention deficit hyperactivity disorder	6.74e-05	0.000173	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.68e-05	0.000172	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—EP300—attention deficit hyperactivity disorder	6.61e-05	0.00017	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.56e-05	0.000169	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.48e-05	0.000167	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EP300—attention deficit hyperactivity disorder	6.2e-05	0.000159	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.04e-05	0.000155	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—EP300—attention deficit hyperactivity disorder	5.95e-05	0.000153	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.75e-05	0.000148	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EP300—attention deficit hyperactivity disorder	5.72e-05	0.000147	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.58e-05	0.000143	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.52e-05	0.000142	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.41e-05	0.000139	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EP300—attention deficit hyperactivity disorder	4.71e-05	0.000121	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.66e-05	0.00012	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EP300—attention deficit hyperactivity disorder	4.57e-05	0.000118	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EP300—attention deficit hyperactivity disorder	4.44e-05	0.000114	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.23e-05	0.000109	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.22e-05	0.000109	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EP300—attention deficit hyperactivity disorder	4.22e-05	0.000109	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.01e-05	0.000103	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.94e-05	0.000101	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EP300—attention deficit hyperactivity disorder	3.47e-05	8.91e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EP300—attention deficit hyperactivity disorder	3.2e-05	8.23e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.05e-05	7.83e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.96e-05	7.6e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	2.92e-05	7.49e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.92e-05	7.49e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	2.87e-05	7.37e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.87e-05	7.37e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.67e-05	6.85e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.33e-05	5.99e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.24e-05	5.76e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.22e-05	5.7e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	1.77e-05	4.54e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	1.75e-05	4.51e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	7.57e-06	1.95e-05	CbGpPWpGaD
